Acceleron Pharma Inc. (XLRN) Reaches $35.74 After 4.00% Up Move; Huntington Bancshares (HBAN) Has 1.22 Sentiment

May 20, 2018 - By Ash

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo

The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) is a huge mover today! The stock increased 3.00% or $1.04 during the last trading session, reaching $35.74. About 469,682 shares traded or 52.65% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 45.87% since May 20, 2017 and is uptrending. It has outperformed by 34.32% the S&P500.The move comes after 5 months positive chart setup for the $1.64 billion company. It was reported on May, 20 by Barchart.com. We have $37.17 PT which if reached, will make NASDAQ:XLRN worth $65.44 million more.

Huntington Bancshares Inc (HBAN) investors sentiment increased to 1.22 in 2017 Q4. It’s up 0.26, from 0.96 in 2017Q3. The ratio has improved, as 230 investment managers opened new and increased stock positions, while 188 sold and decreased positions in Huntington Bancshares Inc. The investment managers in our database now own: 788.75 million shares, down from 791.23 million shares in 2017Q3. Also, the number of investment managers holding Huntington Bancshares Inc in top ten stock positions increased from 6 to 7 for an increase of 1. Sold All: 33 Reduced: 155 Increased: 164 New Position: 66.

More important recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron Pharma’s (XLRN) CEO Habib Dable on Q1 2018 Results – Earnings Call Transcript” on May 14, 2018, also Nasdaq.com published article titled: “Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture …”, Businesswire.com published: “Acceleron Announces Presentations on Luspatercept at the 23” on May 17, 2018. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) was released by: Streetinsider.com and their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” with publication date: May 15, 2018.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 12 have Buy rating, 1 Sell and 3 Hold. Therefore 75% are positive. Acceleron Pharma had 40 analyst reports since August 13, 2015 according to SRatingsIntel. JP Morgan upgraded the stock to “Overweight” rating in Monday, February 26 report. The firm has “Overweight” rating given on Wednesday, April 27 by Barclays Capital. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Outperform”. Morgan Stanley initiated the stock with “Overweight” rating in Thursday, August 13 report. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Outperform” rating given on Monday, January 18 by FBR Capital. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) earned “Outperform” rating by Oppenheimer on Monday, February 1. Oppenheimer maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Friday, June 23 with “Hold” rating. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Hold” rating given on Thursday, September 21 by Credit Suisse. The firm has “Outperform” rating given on Tuesday, November 14 by Credit Suisse. On Thursday, September 29 the stock rating was initiated by Citigroup with “Neutral”.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on August, 2. They expect $-0.64 earnings per share, up 16.88% or $0.13 from last year’s $-0.77 per share. After $-0.58 actual earnings per share reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts 10.34% negative EPS growth.

Investors sentiment decreased to 1.09 in 2017 Q4. Its down 0.72, from 1.81 in 2017Q3. It fall, as 24 investors sold Acceleron Pharma Inc. shares while 32 reduced holdings. 14 funds opened positions while 47 raised stakes. 38.14 million shares or 1.07% more from 37.73 million shares in 2017Q3 were reported. Eagle Asset owns 1.23M shares. Teacher Retirement Systems Of Texas reported 12,606 shares. Bamco Ny invested in 0.01% or 53,880 shares. Congress Asset Ma has invested 0.01% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Metropolitan Life Ny invested in 11,968 shares or 0.01% of the stock. Northern Tru Corporation owns 437,026 shares for 0% of their portfolio. Neuberger Berman Grp Incorporated Ltd, a New York-based fund reported 10,375 shares. Barclays Public Limited Liability Co has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 5,974 shares. Granahan Investment Mgmt Incorporated Ma holds 0.76% or 226,231 shares. Franklin Resource Inc accumulated 435,577 shares. Bnp Paribas Arbitrage Sa stated it has 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Nj State Employees Deferred Compensation Plan invested 0.05% in Acceleron Pharma Inc. (NASDAQ:XLRN). Balyasny Asset Mngmt reported 58,500 shares. Brown Advisory owns 475,871 shares or 0.06% of their US portfolio. Public Employees Retirement Association Of Colorado holds 0% or 3,246 shares in its portfolio.

Since December 15, 2017, it had 0 buys, and 13 selling transactions for $7.84 million activity. Kumar Ravindra also sold $46,205 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, April 3. $814,848 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by MCLAUGHLIN KEVIN F on Tuesday, January 2. George Jean sold $3.76M worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Friday, December 15. POPS RICHARD F sold 37,500 shares worth $1.55M. On Wednesday, January 3 Sherman Matthew L sold $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) or 4,633 shares. The insider Quisel John D sold $183,806. Rovaldi Christopher had sold 3,500 shares worth $134,395.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $1.64 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Since January 1, 0001, it had 0 insider purchases, and 2 sales for $409,277 activity.

Fsi Group Llc holds 6.97% of its portfolio in Huntington Bancshares Incorporated for 575,625 shares. White Elm Capital Llc owns 1.52 million shares or 4.66% of their US portfolio. Moreover, Elizabeth Park Capital Advisors Ltd. has 4.55% invested in the company for 967,196 shares. The Virginia-based Ejf Capital Llc has invested 3.57% in the stock. Rwc Asset Management Llp, a United Kingdom-based fund reported 3.36 million shares.

The stock decreased 1.50% or $0.23 during the last trading session, reaching $15.12. About 5.99M shares traded. Huntington Bancshares Incorporated (HBAN) has risen 14.67% since May 20, 2017 and is uptrending. It has outperformed by 3.12% the S&P500.

More news for Huntington Bancshares Incorporated (NASDAQ:HBAN) were recently published by: Seekingalpha.com, which released: “Huntington Bancshares: A Solid Dividend Investment” on May 16, 2018. Nasdaq.com‘s article titled: “Analysis: Positioning to Benefit within InnerWorkings, Planet Fitness, Huntington Bancshares, Univar, Expedia, and …” and published on May 11, 2018 is yet another important article.

Huntington Bancshares Incorporated operates as a holding firm for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The company has market cap of $16.71 billion. The companyÂ’s Consumer and Business Banking segment offers financial services and products, such as checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, and small business loans; and investments, insurance, interest rate risk protection, and foreign exchange and treasury management services. It has a 15.06 P/E ratio. The Company’s Commercial Banking segment provides corporate risk management and institutional sales, trading, and underwriting services; commercial property and casualty, employee benefits, personal lines, life and disability, and specialty lines of insurance; and brokerage and agency services for residential and commercial title insurance, as well as excess and surplus product lines of insurance.

Analysts await Huntington Bancshares Incorporated (NASDAQ:HBAN) to report earnings on July, 20. They expect $0.29 EPS, up 11.54% or $0.03 from last year’s $0.26 per share. HBAN’s profit will be $320.44M for 13.03 P/E if the $0.29 EPS becomes a reality. After $0.28 actual EPS reported by Huntington Bancshares Incorporated for the previous quarter, Wall Street now forecasts 3.57% EPS growth.

Huntington Bancshares Incorporated (NASDAQ:HBAN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: